Use of 3.0-T MRI for Stereotactic Radiosurgery Planning for Treatment of Brain Metastases: A Single-Institution Retrospective Review

2010 ◽  
Vol 78 (4) ◽  
pp. 1142-1146 ◽  
Author(s):  
Paul A. Saconn ◽  
Edward G. Shaw ◽  
Michael D. Chan ◽  
Sarah E. Squire ◽  
Annette J. Johnson ◽  
...  
2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi41-vi41
Author(s):  
Ethan Srinivasan ◽  
Emily Lerner ◽  
Ryan Edwards ◽  
Aden Haskell-Mendoza ◽  
David Huie ◽  
...  

Abstract INTRODUCTION Stereotactic radiosurgery (SRS) is a highly effective therapy for newly diagnosed brain metastases. Risk factors for new-onset seizures after SRS have not been well established. In this study, we aimed to characterize the variables predictive of seizure risk. METHODS Patients treated with SRS for newly diagnosed brain metastases were retrospectively reviewed at a single institution. Data on baseline demographics, radiation parameters, and clinical courses were collected. RESULTS 120 patients without previous seizure history were identified. Median age was 65 years (56-70.8) and baseline KPS 90 (80-90). 16 (13%) patients developed new-onset seizures within 3 months of SRS. In analyses comparing patients with and without new-onset seizures, there was no association between new-onset seizures and baseline KPS(90:80, p=0.48), prior resection (31%:28%, p=0.76), prior WBRT (6%:10%, p=1), immunotherapy or chemotherapy within 1 month (31%:21%, p=0.52 and 56%:57%, p=1), primary tumor site (p=0.07), number of lesions (2.2:3, p=0.21), cerebellar (25%:37%, p=0.41) or brainstem involvement (19%:14%, p=0.71), irradiated maximum target diameter (2.8:2.0cm p=0.191), maximum target volume (7.6:2.9 cm3 p=0.133), total dose of radiation (25:20Gy, p = 0.12), or use of fractionation (56%:35%, p=0.11). However, there was a significant difference in the total irradiated target volume (11.6 vs. 3.8 cm3, p=0.019) and a trend toward increased post-treatment seizures among patients with a total irradiated volume greater than 10cm3 (20%:9%, p=0.11, OR 2.4 [0.85-6.4]). Patients with seizures were also more likely to have received steroids (69%:34%, p=0.012) and AEDs (28%:15%, p=0.021) prior to SRS. CONCLUSIONS Our data suggest that total treatment volume is associated with new-onset seizures within 3 months of SRS. The association between seizures and exposure to steroids or AEDs prior to SRS may be a surrogate for neurologic symptoms at presentation. Patients undergoing SRS to larger volumes and necessitating prophylactic steroids or AEDs may benefit from counseling or intensification of anti-seizure therapy.


2013 ◽  
Vol 182 (3) ◽  
pp. 481-485 ◽  
Author(s):  
D. Burke ◽  
C. Mascott ◽  
L. Rock ◽  
S. Callinan ◽  
A. Mihai ◽  
...  

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i25-i26
Author(s):  
Matthew Susko ◽  
Michael Garcia ◽  
Lijun Ma ◽  
Jean Nakamura ◽  
David Raleigh ◽  
...  

Abstract BACKGROUND: Recent evidence supports hippocampal sparing during whole brain radiotherapy (HS-WBRT) to improve neurocognitive outcomes in patients with brain metastases (BM). This study sought to quantify the hippocampal dosimetry and treatment efficacy of stereotactic radiosurgery (SRS) to 10 or greater BM to clarify the roles of SRS and WBRT. METHODS: Patients at a single institution treated with SRS to 10 or more BM without WBRT from 1999 to 2016 were retrospectively reviewed. Treatment-related outcomes including overall survival (OS), freedom from progression (FFP), freedom from new metastases (FFNM), and adverse radiation effect (ARE) were quantified. Hippocampal volumes were retrospectively delineated and dosimetry was evaluated in patients treated with upfront SRS. RESULTS: 143 patients with a total of 2198 lesions met criteria for inclusion with 75 patients treated with upfront SRS and 68 treated as salvage from prior WBRT. Median age was 57 (IQR: 46–65) and median KPS 80 (IQR: 70–90). Histologies included breast (n=52), lung (n=49), melanoma (n=30), and other (n=12). Median number of lesions per patient was 13 (IQR 11–17) with median total volume of treatment of 4.1 cc (IQR 2.0–9.9). 12-month FFP per lesion for upfront and salvage treatment was 96.8% (95% CI: 95.5–98.1) and 83.6% (95% CI: 79.9–87.5) respectively (p < 0.001). 12-month FFNM for upfront and salvage FFSRS was 18.8% (95% CI: 10.9–32.3) versus 19.2% (95% CI: 9.7–37.8) respectively (p = 0.90). Mean hippocampal dose was 150 cGy (IQR 100–202). Symptomatic ARE was observed in 2% of patients or 1% of treated lesions. CONCLUSIONS: High rates of local control can be achieved when treating patients with greater than 10 BM with hippocampal doses that are dramatically lower than for HS-WBRT. Hippocampal sparing is readily achievable with expected rates of new metastatic lesions developing in treated patients with low rates of symptomatic ARE.


2018 ◽  
Vol 101 (4) ◽  
pp. 820-829 ◽  
Author(s):  
Katelyn M. Atkins ◽  
Itai M. Pashtan ◽  
Marc R. Bussière ◽  
Kylie H. Kang ◽  
Andrzej Niemierko ◽  
...  

2019 ◽  
Vol 21 (Supplement_4) ◽  
pp. iv13-iv13
Author(s):  
James De Boisanger ◽  
Katherine Mackay ◽  
Cornel Tancu ◽  
Naomi Fersht ◽  
Neil Kitchen ◽  
...  

Abstract Background An increasing number of patients with brain metastases (BM) are having stereotactic radiosurgery (SRS), but it is not known whether this causes epilepsy. Methods We carried out a retrospective review of patients surviving one-year post gamma-knife SRS at the National Hospital for Neurology and Neurosurgery (NHNN) between February 2012 and April 2017. Data on seizures during the pre- and post-SRS periods were collected along with information about the primary tumour, metastasis location and previous treatments, including whole brain radiotherapy (WBRT) and surgery. Results 61 patients were treated with SRS. 6 patients had incomplete records and were excluded. Of the remaining 55, 21 had a seizure at some point. 4 had seizures both pre- and post-SRS, 7 had seizures pre-SRS but not post and 10 patients had de-novo seizures post-SRS. 34 did not have a documented seizure at any point. Of the 14 patients who had seizures post-SRS, 4 also had both WBRT and surgery, 2 had WBRT and 4 had surgery. 100% (4/4) who had WBRT, surgery and SRS went on to have a seizure. Seizures occurred in 11/25 patients who had previous surgery and 7/11 who had previous WBRT. The primary tumour and metastasis location had no obvious impact on seizure incidence. Conclusions The incidence of new seizures post-SRS is low (18%). Previous surgery and/or WBRT may increase seizure incidence post-SRS. The data is currently being reviewed for effect of tumour/ treatment volume, dose delivered, presence of significant oedema and radionecrosis. A larger prospective study is also underway.


2015 ◽  
Vol 51 ◽  
pp. S670
Author(s):  
J. Ward ◽  
J. Armstrong ◽  
K. Armstrong ◽  
C. Mascott ◽  
P. Thirion ◽  
...  

2018 ◽  
Vol 20 (suppl_1) ◽  
pp. i6-i6
Author(s):  
Najmus Sahar Iqbal ◽  
Owen Tilsley ◽  
Andrew Bryant ◽  
Anthony Millin ◽  
David G Lewis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document